Physician

Adam L Palance, MD

According to 2025 Medicare claims, Adam Palance, MD (NPI: 1205032224) practices gastroenterology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. This provider's primary affiliated billing organization is ALLIED DIGESTIVE HEALTH, LLC (NPI: 1265831259; TIN: 463915494) and primary practice location at 07666-4855. Palance is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), Physician Leaders Direct Contracting Entity, LLC (ACO ID: D0171), and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under both the MSSP and REACH models.

Palance's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 675 traditional Medicare patients, billed 1,563 HCPCS/CPT codes, and received $160,910 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 839 prescription claims across 345 beneficiaries totaling $229,568 in drug costs, led by Creon (Lipase/Protease/Amylase). Open Payments data shows 72 records totaling $955. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $193,332 to $160,910. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	500	1,701	$193,332
2016	491	1,434	$157,585
2017	469	1,424	$153,615
2018	414	1,152	$126,437
2019	513	1,150	$138,739
2020	393	754	$85,674
2021	497	1,149	$138,077
2022	710	2,242	$247,487
2023	701	2,282	$252,189
2024	675	1,563	$160,910

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	150	593	$195,270
2016	205	671	$160,729
2017	291	1,149	$201,219
2018	303	1,067	$264,775
2019	343	1,041	$358,088
2020	323	1,001	$324,816
2021	325	1,003	$489,361
2022	336	969	$283,627
2023	347	881	$221,738
2024	345	839	$229,568

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	202	215	$145
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	161	167	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	126	143	$95
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	193	447	$68
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	77	108	$43

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Creon	Lipase/Protease/Amylase	19	779	$59,824
Xifaxan	Rifaximin	25	463	$57,867
Mesalamine	Mesalamine	14	1,124	$16,029
Sod Sulf-Potass Sulf-Mag Sulf	Sodium, Potassium,mag Sulfates	191	218	$11,526
Kristalose	Lactulose	14	380	$4,027

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	72	$955	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam L. Palance, MD?

Tedicare shows public-source Medicare data for Adam L. Palance, MD (NPI 1205032224), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam L. Palance, MD have ACO affiliation data?

Adam L. Palance, MD is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645), Physician Leaders Direct Contracting Entity, LLC (REACH, ACO ID D0171), and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Adam L. Palance, MD?

Adam L. Palance, MD is linked to ALLIED DIGESTIVE HEALTH, LLC (billing NPI 1265831259) in the available physician profile data.

Does Adam L. Palance, MD have Open Payments data?

Adam L. Palance, MD has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.